Biosense Webster, a unit of Johnson & Johnson, has reported the enrollment of the first patient in the SMART-AF IDE study, as well as the treatment of the first patient with the new Thermocool Smarttouch contact force sensing catheter and software module in the U.S. SMART-AF expects to enroll up to 164 patients across the country. The study is trying to demonstrate the safety and effectiveness of the Thermocool Smarttouch in the treatment of symptomatic, drug-refractory, paroxysmal atrial fibrillation Biosense Webster release